HNC: Human Neural Circuits Electrophysiology During Cognition

Psychiatric Disorder Clinical Trial

Official title:

HNC: Human Neural Circuits Electrophysiology During Cognition

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05962424
• Other study ID #: 70198
• Status: Recruiting
• Phase: Phase 1
• Start date: October 5, 2023
• Est. completion date: September 1, 2026

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: Kishandra Patron, BS
• Phone: 6503025923
• Email: kpatron[@]stanford.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Description:

The goal of this proposed research is to record the effects of ketamine on brain activity to understand the changes that occur during antidepressant therapy and the side effect of dissociation. This research is designed to probe altered cognitive states associated with dissociation, depression, and other neuropsychiatric conditions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient in clinical neuro inpatient units at Stanford Medical Center
• Age >18 years old
• Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)

Exclusion Criteria:

• Lifetime psychotic disorder
• Pregnant or nursing females
• Prior adverse ketamine response
• Use of ketamine in past 7 days

Related Conditions & MeSH terms

• Mental Disorders
• Problem Behavior
• Psychiatric Disorder

Intervention

Drug:
• Ketamine Hydrochloride
Ketamine is an FDA-approved dissociative anesthetic.

Locations

Country	Name	City	State
United States	Stanford University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)	The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms.	up to 1 week